chasewnelson on Nostr: Unfortunately, MOV was recommended 13-10. Merck’s case to the FDA repeatedly ...
Unfortunately, MOV was recommended 13-10.
Merck’s case to the FDA repeatedly confused mutation and selection, arguing that all drugs impose selection.
But the problem is mutation: MOV potentiates rare but impactful ‘black swan’ variants. 7/12 https://www.youtube.com/watch?v=fR9FNSJT64M
Merck’s case to the FDA repeatedly confused mutation and selection, arguing that all drugs impose selection.
But the problem is mutation: MOV potentiates rare but impactful ‘black swan’ variants. 7/12 https://www.youtube.com/watch?v=fR9FNSJT64M